OCUL
Ocular Therapeutix, Inc.
Biotechnology · Healthcare · United States
6.97
close · 2026-10-30
value
49
cheaper than peers49
quality
24
stronger fundamentals24
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -4.1% | 63 |
| cash flow yield, 2 years ago | -5.0% | 60 |
| price to book | 2.94× | 57 |
| cash flow yield, 1 year ago | -8.9% | 52 |
| earnings yield, 3 years ago | -13.9% | 52 |
| earnings yield, 2 years ago | -14.6% | 52 |
| earnings yield, 1 year ago | -17.5% | 46 |
| cash flow yield, latest year | -14.2% | 44 |
| earnings yield, latest year | -20.4% | 40 |
| price to sales | 29.41× | 30 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 15.3% | 51 |
| revenue growth | 0.1% | 36 |
| return on equity | -73.0% | 34 |
| operating margin | -609.3% | 30 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | — |
| employees | 325 |
| first trade | 2014-07-25 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.42 | -1.22 | -1.02 | -0.97 |
| free cash flow | -$216.9M | -$136.0M | -$76.3M | -$63.3M |
| net income | -$265.9M | -$193.5M | -$80.7M | -$71.0M |
| revenue | $52.0M | $63.7M | $58.4M | $51.5M |
| unusual items | -$2.5M | -$28.4M | $9.0M | $13.8M |